Investigational ADC QLS5132 showed promising clinical benefit and manageable safety in Phase I trial patients with platinum-resistant ovarian cancer.
Trevi Therapeutics Investor and Analyst Day May 7, 2026, Midtown New York, New York 10:00 a.m. to 12:00 p.m. ET, followed by lunch and open discussions Representatives: Trevi senior management will be ...
BREATH OF HOPE RI is gearing up for its 3rd Annual 5K on May 2, 2026, in Warwick, bringing the community together to raise ...
ILD was detected in about half of AAV cases, and one-third had fibrotic ILD, indicating a substantial pulmonary fibrosis ...
Most of us probably have a solid, big picture idea of behavior that isn’t good for our bodies. Of course, human health is a ...
Prefilled syringes (PFS) preferred on pharmacy benefit; vials preferred on medical benefit RALEIGH, N.C., April 20, 2026 /PRNewswire/ -- Accord BioPharma, the U.S. specialty division of Intas ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients ...
EV-304 trial. The U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental biologics license application for enfortumab vedotin-ejfv (Padcev) in combination with ...
Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced ...
The fatigue and breathlessness program specific to interstitial lung disease is feasible, acceptable, and clinically effective.
This review examines how high-throughput proteomics is expanding precision medicine by improving biomarker discovery, disease ...
Hidden Pneumonia in Calves: Why More Dairies are Using Ultrasound to Catch Respiratory Disease Early
Many calves develop pneumonia days before showing symptoms. Lung ultrasounds are helping veterinarians detect the hidden ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results